Supported by 1,500 peer-reviewed studies, Bertilimumab is a first-in-class antibody which targets and lowers eotaxin-1 levels. It is being studied to see if it will improve outcomes in patients with autoimmune diseases that do not have therapies or the therapies have severe limitations, such as Bullous Pemphigoid and Crohn's & Colitis Read More 

Latest News

PRESS RELEASE March 13, 2017

Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement | Read more 


EVENT March 11, 2017

Preliminary Data with Bertilimumab in an Open Label Phase 2a Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid, presented at the American Academy of Dermatology 2017 Annual Meeting in Orlando, FL. | Read more 


NEWS March 6, 2017

CEO Daniel Teper talks about Bertilimumab following encouraging preliminary data in Phase 2 Study | Read more 


See All News 

Upcoming Events

No upcoming events found

See All Events